Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07505173 Osimertinib mesylate EGFR Mutation Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07505173 clinical trial report covering Osimertinib mesylate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07505745 MOTS-c(Hudson Biotech) Insulin Resistance Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07505745 clinical trial report covering MOTS-c(Hudson Biotech), Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2031260002 SPY-120 Proctitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
JPRN-jRCT2031260002 clinical trial report covering SPY-120, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07505186 Ivarmacitinib Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07505186 clinical trial report covering Ivarmacitinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07506109 Dabrafenib Mesylate Metastatic Microsatellite Stable Colorectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07506109 clinical trial report covering Dabrafenib Mesylate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07505303 Semaglutide (Novo Nordisk) Weight Loss Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07505303 clinical trial report covering Semaglutide (Novo Nordisk), Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07505160 Lisaftoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07505160 clinical trial report covering Lisaftoclax, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07505849 Zanubrutinib Follicular Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07505849 clinical trial report covering Zanubrutinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07504601 Hydroxynorketamine Acute Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07504601 clinical trial report covering Hydroxynorketamine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07504588 Bevacizumab Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07504588 clinical trial report covering Bevacizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07507825 Omacetaxine Mepesuccinate Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07507825 clinical trial report covering Omacetaxine Mepesuccinate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07507513 SSGJ-627 Colitis, Ulcerative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07507513 clinical trial report covering SSGJ-627, Phase 2, endpoints, sponsor, geography, readout timing and development white space.